Executive Management Team
The Executive Management Team manages the day-to-day activities of the company, as well as the long-term strategy. It plays a key role in ensuring Allergy Therapeutics’ continued growth and success. In the UK, the operations are primarily manufacturing and product development, as well as certain market support functions. The Company’s sales and marketing operations are based in Germany, Italy and Spain; these are the three most important European markets for allergy vaccination.
Allergy Therapeutics employs over 480 staff across the group with a strong infrastructure to support the many facets of the business.
Meet the people who ensure that Allergy Therapeutics runs smoothly, maintains high standards and achieves corporate goals.
Chief Executive Officer
Manuel joined the Group in July 2009 following the successful refinancing in which Azure Ventures Limited was the main investor. As Chief Executive Officer, Manuel is responsible for the executive management of group operations, investor relations, and implementation of the Board’s collective decisions overseeing all operational aspects of the Group and directing the long-term strategy.
Please refer to The Board for further information.
Chief Financial Officer
Nick joined Allergy Therapeutics on 9th June 2016 as Finance Director. Nick was most recently at Skyepharma PLC until August 2015 where he was the Group Financial Controller for six years. Prior to that, he had also worked at Quest International (a part of ICI PLC) as the Group Financial Controller (Special Projects), following six years at Deloitte & Touche. Nick has a BSc (Hons) in Economics and is a qualified accountant, being a member of the Institute of Chartered Accountants of England and Wales.
Please refer to The Board for further information.
Professor Tim Higenbottam
Research & Development Director
Tim is a recognised expert in Respiratory Medicine including asthma and has extensive experience in clinical development and regulatory affairs from within the pharmaceutical industry and academia. Tim was Professor of Medicine at Sheffield University between 1995 and 2001 and from 2001, he held senior positions with AstraZeneca before moving onto Chiesi Farmaceutici as a Corporate Director. He joins Allergy Therapeutics from TranScrip Partners where he was a Senior Partner.
Business Development Director
Santiago Puig joined Allergy Therapeutics in September 2009. Prior to this he worked for Alliance Boots as Director of International Trading based in Spain. Previously Santiago has worked for Mepha AG/ Merckle-Ratiopharm Group in Switzerland and Laboratorios Andromaco in Chile.
Santiago started his career at the Deutsche Bank working in corporate finance in Germany and Spain. He has an MBA from IESE, Universidad de Navarra, Barcelona and a degree in economics. As Business Development Director, Santiago is responsible for growing the business through market expansion, M&A, joint ventures and licensing deals.
Prof. Dr. Matthias Kramer
International Medical Director
Matthias Kramer is the International Medical Director of Allergy Therapeutics. He is a medical doctor with outstanding experience in allergy and has also worked at the University of Munich in the Department of Oto-Rhino-Laryngology, Head and Neck Surgery as the Managing Senior Consultant and Head of the Allergy Division. He was also a member of the Executive Board of the university’s “Interdisciplinary Center of Allergy” before moving to Allergy Therapeutics in May 2013.
Nunzio Di Grazia
Regional Director, Italy & Spain
Nunzio started in 2008 as General Manager of Allergy Therapeutics Italian subsidiary and in 2011 was appointed General Manager of Spain and other territories. He has over 25 years’ experience working in the pharmaceutical industry, primarily in Italy, and then in Southern Europe and Latin America.
Prior to this he has worked for Organon, Menarini, for Abbott and for Enteral Nutrition Division. Nunzio has a degree in chemistry and a degree in pharmacy, plus a masters degree in finance and key account management.
Regional Director, Germany & Austria
After studying biology, Bodo Steinert started his career in 1988 at Beecham Wülfing in the allergy department of Bencard.
He worked as a Trainer, Sales Representative and Project Manager. In 1992, he left Beecham to join HAL Allergie, and finally was made Corporate Marketing Manager with responsibility for the whole HAL group. In 2002, he returned to Bencard Allergie as Sales Manager. In 2005 he founded the Austrian subsidiary of Bencard and he is the Managing Director of Germany & Austria. Bodo has substantial experience in the German and Austrian allergology markets, has launched many products in his career and is an expert in implementing marketing & sales concepts.
Bev joined Allergy Therapeutics in 1998 and has extensive experience in Quality Systems. Prior to joining Allergy Therapeutics, she held positions in Quality Assurance and Quality Control within Smithkline Beecham and worked as a Haematologist/ Serologist MLSO in the NHS. In addition Bev has extensive regulatory experience chairing meetings with regulatory agencies in UK, Japan, U.S, Canada and European agencies.
She has authored a variety of scientific posters, spoken at allergy congresses and chaired a session on Quality Systems, Pharmaceutical Development and Validation
Dr. Murray Skinner
Chief Scientific Officer
Murray Skinner joined Allergy Therapeutics in 2004 having previously held positions within quality, scientific and regulatory settings of the pharmaceutical industry including Serologicals, Millipore and Patheon. He has experience in the global market supply of a diverse range of pharmaceutical products including biologics and NCE’s and understands the specific regulations that under-pin product licensure and supply.
Murray completed his PhD with the Medical Research Council and University of London following which he was a visiting lecturer and research fellow at Imperial College. He has also published a number of patents and scientific articles in the field of allergy and vaccine development.